Two key manuscripts that were published in very leading journals, showed that systemic increase in CXCL10, either via epigenetic approach or via targeting the exopeptidase Dipeptidyl-peptidase 4 (DPP4) that induces post-translational modifications of CXCL10 that targets it activity, resulted in increased expression of CXCL10 systemically while limiting cancer development and growth [53,54]. Here, DPP4 is linked to cancer.